Release Date: 25-Jan-2025
HS-20089 represents a novel antibody-drug conjugate (ADC) developed by Hansoh Pharma in partnership with GSK, specifically aimed at treating gynecologic cancers. This investigational agent targets B7-H4, a transmembrane glycoprotein from the B7 family that is significantly overexpressed in various malignancies while exhibiting minimal expression in normal tissues. The drug is linked to a topoisomerase inhibitor (TOPOi) payload, which is released upon interaction with B7-H4-expressing tumor cells. The TOPOi interferes with DNA replication, resulting in cell cycle arrest and subsequent apoptosis of tumor cells.
Download Insight: https://www.kuickresearch.com/report-cancer-drug-conjugates-market-size
Currently, HS-20089 is in Phase 2 clinical trials in China, concentrating on patients diagnosed with ovarian and endometrial cancers. These trials are designed to assess the safety, efficacy, and potential of HS-20089 as a targeted therapeutic option for gynecologic cancers, presenting a promising new strategy for patients with B7-H4-expressing tumors that are challenging to manage with standard treatments.